Periodontitis is a significant public health concern affecting more than
half of those over 30 years of age. Our research on light-activated
antimicrobial agents (LAAAs) has resulted in the development of a novel,
non-invasive therapy that quickly and safely treats periodontitis, thereby
reducing antibiotic usage. This technology was developed for commercial
use through a licence agreement with Ondine Biomedical and their
subsidiary company PDT Inc., as a system called Periowave. Periowave is
available in Canada, Mexico and South East Asia, has been granted CE
marking and FDA approval is currently being sought. To date an estimated
92,000 treatment kits have been sold and 313,000 patients treated. The
system has now also been adapted for use in hospitals to eradicate MRSA
from the anterior nares thereby preventing post-surgical infections.
Impact: Health and Economic Gains:
Research has led to a wearable light source that provides a new way of
treating many skin cancers and acne. The treatment is safe, convenient,
and easy to use bringing benefits to patients and healthcare providers. In
addition it brings economic benefits to Ambicare Health Ltd, the company
For skin cancer treatment, the device gives effective treatment with much
reduced pain. The simplified treatment procedure allows more patients to
be treated in a clinic session. For acne, the device provides a convenient
at-home treatment without the application of drugs or chemicals.
Skin cancer and acne sufferers, the clinics that treat them and Ambicare
The work was led by Professor Ifor Samuel (PHYESTA) working with
Professor James Ferguson (Ninewells Hospital, Dundee).
The wearable light source has changed treatment in the UK and the
Netherlands. The skin cancer treatment is in regular use at more than 25
clinics, and the acne treatment at more than 250 clinics.
Ground breaking and unique research carried out at the Centre for Skin
Sciences at the University of Bradford has led to the realization of
commercial opportunities in two very high-value consumer brands.
Technologies developed in collaboration with multi-national personal-care
and cosmetic companies for the treatment of skin hyper-pigmentation have
been launched on the market and have reached thousands of consumers. The
first product launched by Alliance-Boots (April 2012) is sold within the
UK's premier skincare range (No. 7). Success in Britain led to its launch
in the US, Finland and Thailand. A second product within the Diorsnow
range has been launched by Parfum Dior — a branch of LVMH Moët Hennessy •
Louis Vuitton S.A.
University of Salford researchers have transferred knowledge from
research in the foot health
devices sector into products and services in commercial and clinical
settings, supporting a
£100 billion global healthcare equipment and supplies industry,
contributing to economies and
to quality of life on a daily basis for those with foot and lower limb
health problems, world-wide.
The benefiting partners are part of global businesses and public and
private sector clinical
services and researchers have pioneered the connection of research to
commercial foot health
contexts on a unique scale:
Implementation of photonic quasi-crystals on light emitting diodes (LEDs)
can produce more light using less energy. This technology was brought to
the global market via the successful commercialisation of laboratory
devices derived from research in nanophotonics and the subsequent
development of photonic quasi-crystals by a multi-disciplinary team from
the University of Southampton. The intellectual property of the technology
was acquired and adopted in 2008 by Luxtaltek Corporation, a global
manufacturer of LEDs. In the period 2008-2012 Luxtaltek Corporation, made
total profits of £35 million utilising the photonic quasi-crystal LED
technology, employing more than 300 people in its production facilities.
Research from the Department of Materials Science and Engineering led to
healthcare impact through treatment of burns patients and those with
chronic non-healing wounds using the culture and expansion of the
patient's own skin cells. This impact was achieved by establishing a
product, MySkin®, as the UK's first and only commercially
available complete service for the culture and delivery of patient's skin
cells. It is now used in 11 out of the UK's 12 major burns units for
patients in danger of death from extensive burns. MySkin®
benefits patients, clinicians and nurses and was Biomedical Product of the
Year in 2008 (see Sky News video (2008) on www.Ilika.com).
The university's Pharmacy and Pharmacology unit has developed and
validated novel in silico and in vitro/ex vivo models for
use by the pharma industry to select drug candidates, optimise
formulations, determine the posology for clinical trials and show
bioequivalence. This resulted in: the approval of two products for actinic
keratosis (Picato® and Zyclara®); a generic nail formulation approved for
use based on the demonstration of equivalence using the in vitro/ex
vivo models described with no clinical testing (the first time this
has occurred); and the translation and commercialisation of two dermal
drug delivery-based patented technologies (licensing deals with Sinclair
IS and major pharmaceutical companies).
Extensible fibrillin-rich microfibrils are the template for elastic
fibres that endow dynamic tissues with elastic recoil. Researchers at the
University of Manchester (UoM) showed that microfibrils are degraded in
photoaged skin. We developed a rapid in vivo assay, `The
Manchester Patch Test Assay', which predicts the potential of anti-ageing
products to restore microfibrils in photoaged skin. The assay was used to
demonstrate the efficacy of a Boots Healthcare anti-ageing product and was
showcased on the BBC's Horizon in 2007. Impacts include:
dramatically increased sales for Boots, investment and changes to the
product development strategies of more than 10 international personal care
companies, which have used our assay to support product claims.
Fundamental research on developmental biology of skin and skin appendages
carried out by Prof Colin Jahoda's group has led to progress in the
isolation of specific adult cell populations, understanding of their roles
in skin and hair regeneration, and advances towards clinical applications.
This has led to the development of new methods to replace human hair
follicles, and has been the basis for multi-million dollar research and
development projects by companies in the UK, the US and Japan. The Durham
research has enabled Intercytex Ltd. to attract £27M in VC funding and
£30M in an IPO in 2009, progressing to Phase IIa clinical trials. The US
company Aderans Research Institute has spent $100 million in developing
this "hair cloning" technology. A Durham University spinout company,
ClarinnisBio, was also established in 2009, and has to date attracted ca.
£1M in investment and has employed two scientists, in a region of the UK
that suffers from relatively high levels of unemployment.
Circadian rhythms impact upon a large proportion of human biology.
Disruption due to genetic or environmental (e.g. altered sleep patterns in
shift workers) cues results in reduced quality of life and increased
morbidity for millions of people every year.
Researchers at Surrey first demonstrated blue light sensitivity of the
human circadian system, resulting in increased alertness and mood. This
led to changes in international lighting standards and the development and
use of novel lighting systems, such as blue-enriched polychromatic
lighting. These systems have been employed in homes for older people,
factories, offices, hospitals and schools, increasing health and